Glenview Trust co Sells 1,068 Shares of GSK plc (NYSE:GSK)

Glenview Trust co lowered its holdings in shares of GSK plc (NYSE:GSK) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,869 shares of the pharmaceutical company’s stock after selling 1,068 shares during the period. Glenview Trust co’s holdings in GSK were worth $266,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in GSK. Indiana Trust & Investment Management Co grew its stake in GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in GSK during the fourth quarter worth approximately $26,000. ST Germain D J Co. Inc. grew its stake in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. grew its stake in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Finally, Sierra Ocean LLC acquired a new stake in GSK during the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GSK. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 2.1 %

Shares of GSK stock opened at $40.30 on Tuesday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The stock has a 50 day moving average price of $36.18 and a two-hundred day moving average price of $36.99. The stock has a market capitalization of $83.53 billion, a PE ratio of 25.35, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 3.90%. GSK’s payout ratio is presently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.